4-4-difluoro-4-bora-3a-4a-diaza-s-indacene and aziridine

4-4-difluoro-4-bora-3a-4a-diaza-s-indacene has been researched along with aziridine* in 1 studies

Other Studies

1 other study(ies) available for 4-4-difluoro-4-bora-3a-4a-diaza-s-indacene and aziridine

Article	Year
Fluorine-Doped Carbon Dots with Intrinsic Nucleus-Targeting Ability for Drug and Dye Delivery. Bioconjugate chemistry, 2020, 03-18, Volume: 31, Issue:3 A new type of fluorine-doped carbon dots (FCDs) with the nucleus-targeting capability was prepared and utilized as a promising candidate for drug and dye delivery. Doxorubicin (DOX) and boron dipyrromethene (BODIPY) was used as a model drug and dye, respectively, to construct FCD-DOX and FCD-BODIPY nanocomposites via coassembly with FCDs. The results demonstrate that FCDs can remarkably increase the cellular uptake and delivery of DOX and BODIPY. This work developed a convenient strategy to construct CDs-based nanohybrids for nucleus-targeted bioimaging and cancer treatment. Topics: Aziridines; Biological Transport; Boron Compounds; Carbon; Cell Nucleus; Coloring Agents; Doxorubicin; Drug Carriers; Fluorine; HeLa Cells; Humans; Nanoparticles; Solvents	2020

Article

Year

Fluorine-Doped Carbon Dots with Intrinsic Nucleus-Targeting Ability for Drug and Dye Delivery.

Bioconjugate chemistry, 2020, 03-18, Volume: 31, Issue:3

A new type of fluorine-doped carbon dots (FCDs) with the nucleus-targeting capability was prepared and utilized as a promising candidate for drug and dye delivery. Doxorubicin (DOX) and boron dipyrromethene (BODIPY) was used as a model drug and dye, respectively, to construct FCD-DOX and FCD-BODIPY nanocomposites via coassembly with FCDs. The results demonstrate that FCDs can remarkably increase the cellular uptake and delivery of DOX and BODIPY. This work developed a convenient strategy to construct CDs-based nanohybrids for nucleus-targeted bioimaging and cancer treatment.

Topics: Aziridines; Biological Transport; Boron Compounds; Carbon; Cell Nucleus; Coloring Agents; Doxorubicin; Drug Carriers; Fluorine; HeLa Cells; Humans; Nanoparticles; Solvents

2020